
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board.
“We’re honored to have Dr. Mahendra Rao join our Scientific Advisory Board,” said Sanjeev Luther, President and CEO of Eterna. “His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to bring therapeutics powered by our IP portfolio to the clinic.”
Mahendra Rao, Ph.D., added, “The mRNA-based technologies developed by Dr. Matt Angel and his colleagues are exciting, and I admire the goals the company has set for itself.”
Dr. Mahendra Rao joins the Eterna Therapeutics Scientific Advisory Board with a wealth of experience in bringing novel treatments to and through clinical trials. Mahendra Rao is the Chief Scientific Officer of Vita Therapeutics, Inc., a cell engineering company that uses induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. Dr. Mahendra Rao is internationally recognized for his research involving pluripotent stem cells. After medical training in India, Dr. Rao obtained a doctorate at The California Institute of Technology and embarked on a career in developmental biology that included faculty positions of increasing seniority at the University of Utah and the National Institutes of Health. Dr. Rao has published more than 400 papers on stem cell research and is the inventor of more than twenty patents licensed to various companies.
About Eterna Therapeutics Inc.
Eterna Therapeutics is a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing (UltraSliceTM gene-editing protein), and LNP-based mRNA delivery system (ToRNAdoTM), which is collectively referred to as “mRNA technology platform.” For more information, please visit https://www.eternatx.